Zanco Journal of Medical Sciences
 
Skip Navigation Links
Home
Available Issues
Search
Editorial Board
Information for Authors
Review Process
Copyright
Links and Contacts
  Zanko J Med Sci:  Apr. 2017; 21 (1): 1608-1613

Assessment of serum interleukin-1receptor antagonist (IL-1RN) levels in overweight-obese women and its relation to the cardiovascular risk using Framingham score



Abstract

Background and objective: Interleukin 1 receptor antagonist (IL1RN) is an acute-phase protein that blocks the interleukin-1A and 1B receptors and thereby exerting an anti-inflammatory effect. Expression and secretion of IL1R are under the influence of the metabolic derangement. This study aimed to assess the serum levels of IL1RN in obese subjects taking into consideration its relationship to the cardio-metabolic risk factors in asymptomatic obese subjects.

Methods: This cross-sectional study was conducted in Martyr LaylaQasm Center for Diabetes Mellitus in Erbil, Iraq. A total number of 170 women were recruited and distributed into three groups according to their body mass index (BMI): Group I (normal; ≤ 24.99 kg/m2); Group II (overweight; 25-29.99 kg/m2) and Group III (obese; ≥30 kg/m2). The measurements of cardio-metabolic risk factors including the anthropometric measurements, blood pressure, lipid profiles and the score of cardiovascular events using Framingham Heart Study scoring were determined. Interleukin 1RN and high sensitive C-reactive protein (hs-CRP) were also determined.

Results: Overweight (Group II) and Obese (Group III) women had significant high values of cardio-metabolic risk factors. Group III have significant high values of hs-CRP, and IL IL-1RN levels compared with Group I and II. The serum levels of IL-1RN are increased as the body mass index is increased but is not associated with increased risk of the cardiovascular events or a proportional increased of hs-CRP. A significant correlation between serum IL-1RN levels with cardiovascular risk (%) was observed among subjects of Group II. 

Conclusion: The study concludes that serum IL-1RN levels are significantly increased withy body mass index in over-weight-obese subjects and its increment is not correlated with low-grade of inflammation assessed by measurement of hs-CRP. The clinical significant of determination of IL-1NR to predict cardiovascular events risk is marginal in overweight subjects.  

Keywords: Interleukin1 RNR; Cardiovascular risk; Overweight-obese women.


Reference

1. Erion JR, Wosiski-Kuhn M, Dey A, Hao S, Davis CL, Pollock NK, et al. Obesity elicits interleukin 1-mediated deficits in hippocampal synaptic plasticity. J Neurosci 2014; 34(7): 2618–31.

2. Khalkhal A, Haddar A, Semiane N, Mallek A, Abdelmalek A, Castex F, et al. Obesity, insulin resistance and diabetes in the sand rat exposed to a hypercaloric diet; possible protective effect for IL1-beta. C R Biol 2012; 335(4):271–8. 

3. Juge-Aubry CE, Meier CA. Immunomodulatory actions of leptin. Mol Cell Endocrinol 2002; 194 (1-2):1–7

4. Dasu MR, Devaraj S, Jialal I. High glucose induces IL-1beta expression in human monocytes: mechanistic insights. Am J Physiol Endocrinol Metab 2007; 293(1):E337–46

5. Böni-Schnetzler M, Boller S, Debray S, Bouzakri K, Meier DT, Prazak R, e al. Free fatty acids induce a proinflammatory response in islets via the abundantly expressedinterleukin-1 receptor I. Endocrinology 2009; 150(12):521829.

6. Somm E, Henrichot E, Pernin A, Juge-Aubry CE, Muzzin P, Dayer JM, et al. Decreased fat mass in interleukin-1 receptor antagonist-deficient mice: impact on adipogenesis, food intake, and energy expenditure. Diabetes 2005; 54(12):3503–9.

7. Yang SA. Exonic polymorphism (rs315952, Ser133Ser) of interleukin 1 receptor antagonist (IL1RN) is related to overweigh/obese with hypertension. J Exerc Rehabil 2014; 10(5):332-–6.

8. Interleukin 1 Genetics Consortium. Cardiometabolic effects of genetic upregulation of the interleukin 1 receptor antagonist: a Mendelianrandomisation analysis. Lancet Diabetes Endocrinol 2015; 3(4):243–53

9. Saltevo J, Laakso M, Jokelainen J, Keinänen-Kiukaanniemi S, Kumpusalo E, Vanhala M. Levels of adiponectin, C-reactive protein and interleukin-1 receptor antagonist are associated with insulin sensitivity: a population-based study. Diabetes Metab Res Rev 2008; 24(5):378–83.

10. Bissonnette S, Saint-Pierre N, Lamantia V, Cyr Y, Wassef H, Faraj M. Plasma IL-1Ra: linking hyperapoB to risk factors for type 2 diabetes    independent of obesity in humans. Nutr Diabetes 2015; 5:e180.

11. Siklova M, Simonsen L, Polak J, Stich V, Bülow J. Effect of short-term hyperglycemia on adipose tissue fluxes of selected cytokines in vivo during multiple phases of diet-induced weight loss in obese women. J Clin Endocrinol Metab 2015; 100(5):1949–56.

12. D'Agostino RB Sr, Vasan RS, Pencina MJ, Wolf PA, Cobain M, Massaro JM, et al. General cardiovascular risk profile for use in primary care: the Framingham Heart Study. Circulation 2008; 117(6):743–53.

13. Andersson N, Strandberg L, Nilsson S, Ljungren O, Karlsson MK, Mellström D, et al. Variants of the interleukin-1 receptor antagonist gene are associated with fat mass in men. Int J Obes (Lond) 2009; 33(5):525–33.

14. Latkovskis G, Licis N, Kalnins U. C-reactive protein levels and common polymorphisms of the interleukin-1 gene cluster and interleukin-6 gene in patients with coronary heart disease. Eur J Immunogenet 2004; 31(5):207–13.

15. Hoppmann P, Koch W, Laugwitz KL, Kastrati A. Genetic risk of restenosis after percutaneous coronary interventions in the era of drug-eluting stents. Coronary Artery Dis 2014; 25(8):658–64.

16. Fragoso JM, Delgadillo H, Llorente L, Chuquiure E, Juárez-Cedillo T, Vallejo M, et al. Interleukin 1 receptor antagonist polymorphisms are associated with the risk of developing acute coronary syndrome in Mexicans. Immunol Lett 2010; 133(2):106–11.

17. Xu P, Li Y, Zhang PA, Li XY, Li GS. The distribution of gene polymorphisms in the intron 2 and exon 2 of interleukin-1 receptor antagonist and their correlation with the serum lipoprotein level. Zhonghua Liu Xing Bing Xue Za Zhi 2004; 25(6):522–6.

This work is licensed under a Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License.